Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + Erlotinib in Erlotinib-Resistant Lung Adenocarcinoma
NCT00716456Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2008
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in lung adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2008; status: completed.
02
Drugs
KL-140
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT00716456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00716456.